Developments Matricelf advances toward first-in-human trial of spinal cord injury treatment Matricelf (TASE: MTLF) announced the successful completion of its comprehensive GLP safety study for its engineered neural tissue implant, achieving all predefined study endpoints with no abnormal findings. According to... June 17, 2026